<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857010</url>
  </required_header>
  <id_info>
    <org_study_id>2012-003900-11</org_study_id>
    <nct_id>NCT02857010</nct_id>
  </id_info>
  <brief_title>Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure</brief_title>
  <acronym>Liveradvance</acronym>
  <official_title>Therapeutic Effects of Allogenic Mesenchymal Stem Cells in Cirrhotic Patients With Acute-on-chronic Liver Failure. A Double-blind Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pere Gines</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind placebo randomized controlled trial evaluating the clinical efficacy of&#xD;
      allogenic bone marrow derived mesenchymal stem cells in cirrhotic patients with&#xD;
      acute-on-chronic liver failure&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: The most important cause of death in patients with cirrhosis is the development&#xD;
      of Acute-on-Chronic Liver Failure (ACLF), a syndrome recently redefined with high mortality.&#xD;
      The only effective treatment for ACLF is liver transplantation. However, available organs are&#xD;
      limited. Other treatments, such as artificial liver support systems, do not improve survival.&#xD;
      ACLF is characterized by increased systemic inflammatory state together with impaired liver&#xD;
      regeneration what leads to multiorgan failure. Mesenchymal stem cell (MSC) therapy is an&#xD;
      attractive strategy for ACLF owing to the immunomodulatory and regenerative properties of&#xD;
      these cells. Aim: To investigate the effects of allogeneic bone marrow MSCs transplantation&#xD;
      on liver and other organ functions and systemic inflammation in patients with ACLF. Altruist&#xD;
      bone marrow donors will be the source of MSCs. Design and methodology: randomized,&#xD;
      double-blind phase I placebo-controlled trial aimed at comparing placebo (solution without&#xD;
      cells) and MSCs (4 doses of 2 x 106/kg administered on days 1, 4, 11 and 18). Thirty&#xD;
      patients, 15 per group will be included. ACLF will be defined by the CLIF SOFA score and&#xD;
      patients stratified according to severity. Outcomes evaluated will be: 1) Organ function&#xD;
      (CLIF SOFA and CLIF-C ACLF score); 2) Liver (Child-Pugh and MELD scores,serum bile acids,&#xD;
      ammonia and lactate levels), circulatory (systemic and splanchnic hemodynamics, renin,&#xD;
      noradrenalin) and endothelial function (nitric oxide, von Willebrand factor); 3 Inflammatory&#xD;
      response (serum cytokine panel and transcriptomic analysis of monocytes and polymorphonuclear&#xD;
      cells from peripheral blood); 4) Survival at 28 days, 3 and 12 months; and 5) Safety.&#xD;
      Expected results: Therapy with MSCs could have beneficial effects on the evolution of&#xD;
      patients with ACLF (modulation of inflammatory response and improvement of liver and&#xD;
      extra-hepatic organ function) what could translate into an improvement on short-term&#xD;
      survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in organ function: chronic liver failure-sequential organ failure assessment (CLIF-SOFA)</measure>
    <time_frame>Change from Baseline CLIF-SOFA score at 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Child-Pugh score as a marker of liver function</measure>
    <time_frame>Change from Baseline Child-Pugh score at 28 days, 90 days, one year and 2 years</time_frame>
    <description>Child-Pugh</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model for End-stage Liver Disease (MELD) score as a marker of liver function</measure>
    <time_frame>Change from Baseline MELD score at 28 days, 90 days, one year and 2 years</time_frame>
    <description>MELD scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum bile acids as a surrogate marker of liver function</measure>
    <time_frame>Change from Baseline serum bile acids at 28 days</time_frame>
    <description>serum bile acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ammonia levels as a surrogate marker of liver function</measure>
    <time_frame>Change from Baseline serum ammonia at 7, 21 and 28 days</time_frame>
    <description>ammonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate levels as a surrogate marker of liver function</measure>
    <time_frame>Change from Baseline serum lactate levels at 7, 21 and 28 days</time_frame>
    <description>lactate levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic portal venous gradient (HPVG)</measure>
    <time_frame>Change from Baseline HPVG at 21 days</time_frame>
    <description>HPVG in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function measured by nitric oxide levels</measure>
    <time_frame>Change from Baseline serum nitric oxide levels at 7, 21 and 28 days</time_frame>
    <description>Nitric oxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function measured by von Willebrand factor levels</measure>
    <time_frame>Change from Baseline serum von Willebrand factor levels at 7, 21 and 28 days</time_frame>
    <description>von Willebrand factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function measured by serum creatinine</measure>
    <time_frame>Change from Baseline serum creatinine at 7, 21 and 28 days</time_frame>
    <description>serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function measured by Blood urea nitrogen (BUN)</measure>
    <time_frame>Change from Baseline serum BUN at 7, 21 and 28 days</time_frame>
    <description>serum BUN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine neutrophil gelatinase-associated lipocalin (NGAL) as a surrogate marker of renal function</measure>
    <time_frame>Change from Baseline NGAL at 7, 21 and 28 days</time_frame>
    <description>urine neutrophil gelatinase-associated lipocalin (NGAL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory response</measure>
    <time_frame>Change from Baseline cytokine panel at 4, 11 and 18 days</time_frame>
    <description>Serum cytokine panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptome analysis</measure>
    <time_frame>Change from Baseline transcriptome analysis at 7-8 days and 12-18 days</time_frame>
    <description>Transcriptome analysis of monocytes and polymorphonuclear cells from peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants alive</measure>
    <time_frame>Number of participants alive at 28 days, 3 months, 12 months and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by World Health Organization (WHO) classification for acute and subacute toxicity</measure>
    <time_frame>Number of participants with treatment-related adverse events as assessed by WHO classification for acute and subacute toxicity at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in chronic liver failure C acute on chronic liver failure score (clif C ACLF)</measure>
    <time_frame>Change from Baseline clif C ACLF score at 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute on Chronic Hepatic Failure</condition>
  <arm_group>
    <arm_group_label>Allogenic Mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous allogenic bone marrow derived mesenchymal stem cells: 4 doses of 2 x 106/kg administered on days 1, 4, 11 and 18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Solution without cells on days 1, 4, 11 and 18</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogenic mesenchymal stem cells</intervention_name>
    <description>Cell therapy</description>
    <arm_group_label>Allogenic Mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Serum without stem cells</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  ACLF grade 1, 2 or 3 (Canonic criteria)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute or subacute liver failure without cirrhosis&#xD;
&#xD;
          -  ACLF grade 1 with response to medical therapy&#xD;
&#xD;
          -  Evidence of current malignancy including hepatocellular carcinoma (any grade) or&#xD;
             alphafetoprotein &gt; 400 ng/ml&#xD;
&#xD;
          -  Previous personal history of malignancy (active or in complete remission) or familiar&#xD;
             history of hereditary cancer.&#xD;
&#xD;
          -  Moderate or severe chronic heart failure (NYHA III-IV)&#xD;
&#xD;
          -  Renal replacement therapy&#xD;
&#xD;
          -  Severe chronic pulmonary disease (GOLD III-IV)&#xD;
&#xD;
          -  Gastrointestinal bleeding in the last 5 days&#xD;
&#xD;
          -  Previous liver transplantation&#xD;
&#xD;
          -  Immunosuppressive therapy&#xD;
&#xD;
          -  Extrahepatic cholestasis&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Pregnant of breastfeeding women&#xD;
&#xD;
          -  Pre-menopausal women who are of child bearing potential and are not practicing an&#xD;
             acceptable method of birth control.&#xD;
&#xD;
          -  Participation in any investigational trial in the last 3 months&#xD;
&#xD;
          -  Active addition to illegal drugs&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Patients who can not provide prior informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Fernandez, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pere Ginès, MD, PhD</last_name>
    <phone>0034 2275400</phone>
    <phone_ext>383249</phone_ext>
    <email>Pgines@clinic.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Javier Fernandez, MD, PhD</last_name>
    <phone>0034 2275400</phone>
    <phone_ext>3329</phone_ext>
    <email>Jfdez@clinic.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PERE GINES, MD PhD</last_name>
      <phone>0034932275400</phone>
      <phone_ext>1713</phone_ext>
      <email>PGINES@clinic.ub.es</email>
    </contact>
    <contact_backup>
      <last_name>Javier Fernandez, MD PhD</last_name>
      <phone>00342275400</phone>
      <phone_ext>3329</phone_ext>
      <email>Jfdez@clinic.cat</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>August 4, 2016</last_update_submitted>
  <last_update_submitted_qc>August 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Pere Gines</investigator_full_name>
    <investigator_title>Head of the Liver Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

